Evidence map›Paper›PMID 16501108›Full record

ArticleJournal of virology2006

RNase L plays a role in the antiviral response to West Nile virus.

Svetlana V Scherbik, Jayashree M Paranjape, Bronislava M Stockman, Robert H Silverman, Margo A Brinton

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 144 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Shiftless inhibits flavivirus replication in vitro and is neuroprotective in a mouse model of Zika virus pathogenesis.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  8. Review
  9. Article
  10. Zika virus employs the host antiviral RNase L protein to support replication factory assembly.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Host genetic control of mosquito-borne Flavivirus infections.Mammalian genome : official journal of the International Mammalian Genome Society · 2018
    Review
  19. Article
  20. Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Svetlana V ScherbikDepartment of Biology, Georgia State University, P.O. Box 4010, Atlanta, Georgia 30302-4010, USA.
Jayashree M Paranjape
Bronislava M Stockman
Robert H Silverman
Margo A Brinton
Georgia State University · USCleveland Clinic · US

Funding

REGULATION OF 2-5A-DEPENDENT RNASE LEVELS OF INTERFERONR01CA044059 · NCI · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI SILVERMAN, ROBERT H. · 1986 to 2015
$6.1M
Functional analysis of flavivirus genetic resistance.R01AI045135 · NIAID · GEORGIA STATE UNIVERSITY · PI BRINTON, MARGO A, KAUR, PARJIT · 2000 to 2018
$4.8M
NCI NIH HHS CA44059NCI NIH HHS R01 CA044059NIAID NIH HHS AI045135NIAID NIH HHS R01 AI045135
6 · The paper itself

Abstract

Alleles at the Flv locus determine disease outcome after a flavivirus infection in mice. Although comparable numbers of congenic resistant and susceptible mouse embryo fibroblasts (MEFs) are infected by the flavivirus West Nile virus (WNV), resistant MEFs produce approximately 100- to 150-fold lower titers than susceptible ones and flavivirus titers in the brains of resistant and susceptible animals can differ by >10,000-fold. The Flv locus was previously identified as the 2'-5' oligoadenylate synthetase 1b (Oas1b) gene. Oas gene expression is up-regulated by interferon (IFN), and after activation by double-stranded RNA, some mouse synthetases produce 2-5A, which activates latent RNase L to degrade viral and cellular RNAs. To determine whether the lower levels of intracellular flavivirus genomic RNA from resistant mice detected in cells at all times after infection were mediated by RNase L, RNase L activity levels in congenic resistant and susceptible cells were compared. Similar moderate levels of RNase L activation by transfected 2-5A were observed in both types of uninfected cells. After WNV infection, the mRNAs of IFN-beta and three Oas genes were up-regulated to similar levels in both types of cells. However, significant levels of RNase L activity were not detected until 72 h after WNV infection and the patterns of viral RNA cleavage products generated were similar in both types of cells. When RNase L activity was down-regulated in resistant cells via stable expression of a dominant negative RNase L mutant, approximately 5- to 10-times-higher yields of WNV were produced. Similarly, about approximately 5- to 10-times-higher virus yields were produced by susceptible C57BL/6 RNase L-/- cells compared to RNase L+/+ cells that were either left untreated or pretreated with IFN and/or poly(I) . poly(C). The data indicate that WNV genomic RNA is susceptible to RNase L cleavage and that RNase L plays a role in the cellular antiviral response to flaviviruses. The results suggest that RNase L activation is not a major component of the Oas1b-mediated flavivirus resistance phenotype.

Indexed as

2',5'-Oligoadenylate SynthetaseAdenine NucleotidesAnimalsCell LineCricetinaeEndoribonucleasesEnzyme ActivationGene Expression RegulationHumansInterferonsMiceMice, CongenicMice, Inbred C3HMice, Inbred C57BLOligoribonucleotidesPoly I-C2-5A-dependent ribonuclease2',5'-oligoadenylate2',5'-Oligoadenylate SynthetaseAdenine NucleotidesEndoribonucleasesInterferonsOligoribonucleotidesPoly I-CRNA, Viral

Identifiers

PMID16501108
PMCPMC1395436
OpenAlexW2157271780

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.